Hypertrophic And Keloid Scar Treatment Market To Reach $1,680.2 Million By 2033

Hypertrophic And Keloid Scar Treatment Market Growth & Trends

The global hypertrophic and keloid scar treatment market size is anticipated to reach USD 1,680.2 million by 2033 witnessing a CAGR of 10.4% from 2026 to 2033, according to a new report by Grand View Research, Inc. This can be attributed to the rise in the number of road accidents & burn cases. For instance, according to an article by American Burn Association, more than 400,000 people are treated for burn injuries every year. Similarly, as per Children Safety Network, each year more than 100,000 children & adolescents are treated for burn injuries.

Moreover, as per National Highway Traffic Safety Administration, an estimated 31,720 people have died in road accidents in the first nine months of 2021. This number has increased by 12% as compared to 2020. Similarly, as per Live Mint, 3,54,796 cases of road accidents were reported by India in the year 2020. Thus, due to the above-mentioned factors, the t market is estimated to witness significant growth over the forecasted period.

Similarly, rising awareness regarding aesthetic appeal and availability of surgeries is expected to boost the industry's growth. For instance, as per Medscape, 200 million incisions are performed globally. Moreover, as per a similar source, an estimated 170,000 scar revision surgeries are performed every year in the U.S. alone. Thus, such instances are expected to propel industry adoption over time.

Additionally, the rising incidence rate of skin disorders such as eczema, and acne is expected to increase the demand for hypertrophic and keloid scar treatments. For instance, as per a study published by NCBI, patients with eczema are at higher risk of developing a keloid scar. Moreover, according to National Eczema Association, 36.10 million people i.e., about 10.1% of the total U.S. population have some or other form of eczema. Thus, rising cases of eczema & risk of formation of keloid scars due to it are predicted to drive the market growth.

Furthermore, the decline in the population suffering from COVID-19 is anticipated to boost the growth of the industry. Companies in the market are opting for various strategies such as partnerships, and distribution agreements. For instance, in November 2021, Sonoma Pharmaceuticals & Dyamed Biotech announced the expansion of their long-term partnership. This partnership is intended to expand the availability of their products in South Asian countries such as Malaysia, Indonesia, Thailand & Singapore. Therefore, such instances are expected to boost the growth of the industry over the forecast period.

 Request a free sample copy or view the report summary: Hypertrophic And Keloid Scar Treatment Market Report

Hypertrophic And Keloid Scar Treatment Market Report Highlights

• The hypertrophic segment led the hypertrophic & keloid scar treatment market, accounting for the largest revenue share of 59.9% in 2025. Hypertrophic scars (HTS) are an abnormal form of wound healing characterized by excessive deposition of extracellular matrix (ECM), particularly collagen, within the boundaries of the original injury site.

• The topical products segment led the hypertrophic & keloid scars treatment industry, accounting for the largest revenue share of 61.5% in 2025. Topical products represent a key non-invasive segment in the hypertrophic and keloid scars market, primarily used to reduce inflammation, flatten raised scars, improve pigmentation, and prevent recurrence after surgery or intralesional therapy.

• The business to consumers (B2C) segment dominated the hypertrophic & keloid scar treatment market in 2025 and is expected to grow at the fastest CAGR over the forecast period. B2C channels enable manufacturers to directly reach patients through retail pharmacies, online platforms, e-commerce marketplaces, company-owned websites, and over-the-counter (OTC) sales channels.

• The Asia Pacific hypertrophic & keloid scar treatment industry accounted for the largest revenue share of 46.1% in 2025, and is expected to grow at the fastest CAGR of 12.4% over the forecast period. The market is strongly influenced by the high prevalence of dermatological conditions and injury-related wounds that frequently result in abnormal scar formation. 

Hypertrophic And Keloid Scar Treatment Market Segmentation

Grand View Research has segmented the hypertrophic and keloid scar treatment market report based on scar type, product, end use, and region:

Hypertrophic & Keloid Scar Treatment Scar type Outlook (Revenue, USD Million, 2021 - 2033)

• Hypertrophic Scar

• Keloid Scar

Hypertrophic & Keloid Scar Treatment Product Outlook (Revenue, USD Million, 2021 - 2033)

• Topical Products

  • Silicone Sheets

  • Creams

  • Gels

  • Others

• Laser Products

  • Pulsed Dye Lasers

  • CO2 Lasers

  • Others

• Injectables

Hypertrophic & Keloid Scar Treatment End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Business to Business (B2B)

  • Hospitals

  • Clinics

• Business to Consumers (B2C)

  • Pharmacies

  • Online/E-commerce

  • Hypermarkets &Supermarkets

  • Others

Hypertrophic & Keloid Scar Treatment Regional Outlook (Revenue, USD Million, 2021 - 2033) 

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Hypertrophic And Keloid Scar Treatment Market

• Smith & Nephew

• Merz Pharmaceuticals, LLC

• Sonoma Pharmaceuticals, Inc.

• CCA Industries, Inc.

• Newmedical Technology Inc.

• Mölnlycke Health Care AB

• Perrigo Company plc

• Rejuvaskin/ Scar Heal Inc.

• Alliance Pharma PLC

• Hanson Medical, Inc.

• Lumenis Be Ltd.

• CYNOSURE